Effervescent or liposomal not capsules or tablets
1988 DOI: 10.1016/0014-5793(88)80509-x PMID: 3169264 Read on PubMed Advances in Experimental Medicine and Biology Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation Miller DM, DeSilva D, Pickart L 1990 DOI: 10.1007/978-1-4684-5730-8_11 PMID: 2244543 Read on PubMed Cosmetics GHK and DNA: Resetting the Human Genome to Health Pickart L, Vasquez-Soltero JM, Margolina A 2014 DOI: 10.1155/2014/151479 PMID: 25210707 Read on PubMed FASEB Journal Tripeptide-copper complex GHK-Cu(2+) transiently activates the inflammatory response in Jurkat T-cells and B-cell lymphoma cells Gruchlik A, Jurzak M, Chodurek E, Dzierewicz Z 2010 DOI: 10.1096/fasebj.24.1_supplement.lb87 PMID: 20639517 Read on PubMed Experimental Dermatology Effect of the tripeptide-copper complex L-alanyl-L-histidyl-L-lysine-Cu2+ on hair growth in C57BL/6 mice Pyo HK, Yoo HG, Won CH, et al
Recognising red-flag symptoms (e.g
Activates natural energy*
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D
Traditional drug development approaches rely on iterative experimental trial-and-error cycles that are both time-intensive and prohibitively costly, with the average cost of bringing a new drug to market reaching up to $2.23 billion (Wouters et al., 2020)